Pediatric Postoperative Analgesia Herniorrhaphy Study
← catalyst calendarSponsored by Heron Therapeutics (industry) · HRTX — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Withdrawn due to lack of enrollment.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2023 | estimated | When the study began enrolling |
| Primary completion | Nov 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2019-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Analgesia
Interventions
- Drug: HTX-011
- Drug: Bupivacaine HCl
- Drug: HTX-011
- Drug: HTX-011
- Drug: HTX-011
- Device: Luer Lock Applicator
Primary outcomes
what the primary-completion date above is the date OFArea under the concentration-time curve (AUC) from Time 0 extrapolated to infinity (AUCinf)
measured 72 hours
Maximum concentration (Cmax)
measured 72 hours
Time of occurrence of maximum concentration (Tmax)
measured 72 hours
Permalink · HRTX's whole pipeline · Catalyst calendar · Every registered study · What changed